BILESSGLU® is the commercial brand name of Chiglitazar Sodium, a novel peroxisome proliferator-activated receptor (PPAR) pan-agonist developed domestically in China. It can activate PPARα, PPARγ and PPARδ receptors, improving insulin resistance and regulating glucose and lipid metabolism.
Main Indications
For the treatment of type 2 diabetes mellitus in adult patients, to improve glycemic control. It can be used as monotherapy for patients with inadequate blood sugar control by diet and exercise alone, or combined with metformin.
Clinical Research
Phase III clinical trials demonstrated that chiglitazar sodium significantly reduced HbA1c and fasting plasma glucose in type 2 diabetic patients. It also showed favorable effects on lipid profiles, with acceptable overall safety profile. The clinical program supported its new drug application for type 2 diabetes in China.
Common Side Effects
Common adverse reactions include edema, hypoglycemia (when combined with other antidiabetic agents), elevated transaminase, hyperlipidemia, weight gain. Rare serious reactions include liver injury, heart failure-related events.
Approval Status in China
BILESSGLU® (Chiglitazar Sodium Tablets) was officially approved for marketing in China in 2021, with the specification of 16mg. It is a domestically innovative prescription drug for type 2 diabetes.
Buy BILESSGLU (Chiglitazar Sodium Tablets) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
